NCT02274285View on ClinicalTrials.gov

DTaP-IPV/Hib Vaccine Primary & Booster Vaccinations Versus Co-administration of DTaP-IPV and Hib Vaccine in Japanese Infants

PHASE3CompletedINTERVENTIONAL
Enrollment

424

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

May 28, 2016

Study Completion Date

May 28, 2016

Conditions
TetanusDiphtheriaPertussisPoliomyelitisBacterial Meningitis
Interventions
BIOLOGICAL

DTaP-IPV/Hib Combined vaccine

0.5 mL, Subcutaneously. 3 times, each given 3 to 8 weeks apart

BIOLOGICAL

DTaP-IPV vaccine and Hib vaccine

0.5 mL each, Subcutaneously, 3 times, each given 3 to 8 weeks apart

BIOLOGICAL

DTaP-IPV/Hib Combined vaccine

0.5 mL, Intramuscularly. 3 times, each given 4 to 8 weeks apart

Trial Locations (12)

Unknown

Aichi

Chiba

Fukui

Fukuoka

Gunma

Hokkaido

Miyagi

Nagano

Osaka

Shizuoka

Tokyo

Yamanashi

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT02274285 - DTaP-IPV/Hib Vaccine Primary & Booster Vaccinations Versus Co-administration of DTaP-IPV and Hib Vaccine in Japanese Infants | Biotech Hunter | Biotech Hunter